Can-Fite completes dosing of first cohort in Phase I liver drug trial
This trial is currently being conducted in the US by a clinical research organization, specializing in the conductance of Phase I studies. The drug is orally administered to
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.